Morana Jovan-Embiricos

Morana Jovan-Embiricos, listed as board member, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in TCR2 Therapeutics Inc., Kalaris Therapeutics, Inc. and Cullinan Therapeutics, Inc. Over a trading history stretching from 6 June 2014 to 6 June 2024, the count stands at 101 filings.

Both buying and selling appear: 9 purchases worth €57.7M, against 55 sales worth €12.3M. Netting one side against the other leaves €45.3M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 9 share grants and 2 option exercises.

Half of the purchases are above €2.2M and half below. Of 7 purchases, 7 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. For 4 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 50% of cases, with a median move of -0.4%. These figures describe past trades and do not predict future prices.

Most recently, on 7 June 2024, the filings show a share grant in Kalaris Therapeutics, Inc. The clock since the last published purchase (14 January 2021) now reads 2,124 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.